Skip to main content
Premium Trial:

Request an Annual Quote

GenTel BioSurfaces, UniProt Consortium, Ingenuity, Andrew von Eschenbach, Lester Crawford, Douglas Throckmorton, Cheri Walker, Chuck Piazza, Gustavo Salem, and more

Premium

New Products

GenTel BioSurfaces announced last week the launch of its Path HTS platform for high-throughput quantitative immunoassays.

The Path HTS system uses GenTel's proprietary ultra-thin nitrocellulose technology, and includes accessories that enable use with existing microarray instrumentation, including microarray spotters and scanners.


The UniProt Consortium, comprising the European Bioinformatics Institute, the Swiss Institute of Bioinformatics, and the Protein Information Resource, has released UniProt 6.0 at http://www.uniprot.org. In the current release, UniProtKB includes 2,299,834 entries (the UniProtKB/Swiss-Prot section contains 194,317 and the UniProtKB/TrEMBL section contains 2,105,517).


Ingenuity has released Ingenuity Pathways Analysis 3.0. Features include the ability to analyze microarray and proteomics data in the context of pathways; create customized pathways for targets, biomarkers, processes, and diseases; integrate proprietary data into any pathway; and share analyses and personalized pathways with colleagues. Trials are available at http://www.ingenuity.com/trial.

 

Movers & Shakers

Andrew von Eschenbach has been named acting commissioner of the US Food and Drug Administration, following the resignation of former commissioner Lester Crawford last week.

Von Eschenbach has been director of the National Cancer Institute, part of the National Institutes of Health, since January 2002. Before that, he worked as a doctor and executive at the M D Anderson Cancer Center in Houston. Von Eschenbach has said that he intends to act as both head of the FDA and director of NCI.

The appointment ends the tenure of Crawford who resigned last Friday.

Crawford, a veterinarian and expert on food safety, was named deputy commissioner of the agency in early 2002 before his tenure as acting commissioner began last year.

In a message to colleagues, Crawford cited his age — 67 — as a factor in his decision to step aside.


Douglas Throckmorton has been named deputy director of the Center for Drug Evaluation and Research by the FDA. Throckmorton joined the FDA in 1997 and has been acting deputy director of CDER since May 2004.

Before joining the FDA, Throckmorton practiced medicine and held academic appointments at the Medical College of Georgia and the VA Medical Center in Augusta, GA.


Cheri Walker has been named vice president of mergers and acquisitions of Qiagen. Walker joined the firm last week from Invitrogen, where she most recently held the position of vice president of proteomics. She had joined Invitrogen in December 2003 as vice president, corporate development. Prior to working at Invitrogen, Walker was an equity analyst with Deutsche Bank covering the life sciences tools industry.


Invitrogen promoted Chuck Piazza to the position of vice president and general manager of proteomics, following Walker's departure. Piazza had held the position of vice president and general manager of protein arrays before the promotion. Invitrogen also named Don Daut vice president and general manager of its Antibody Center of Excellence.


Assay Designs has appointed Gustavo Salem as its new president and CEO, the Ann Arbor, Mich.-based biotech firm said last week.

Prior to joining Assay Designs, Salem held a variety of positions at Bio-Rad Laboratories, including division manager of protein separations and business unit manager for biomaterials. Prior to this, he held a series of sales and marketing positions at PerSeptive Biosystems, Beckman Instruments, and Amersham.


GenoLogics Life Sciences Software expanded its management team this week with several new appointments.

The Canadian bioinformatics company named Greg Kinch as vice president of sales, and joined GenoLogics from Silicon Genetics, now Agilent Technologies. He previously held sales leadership positions at Genomic Solutions, BI Systems, and other companies in the life sciences industry.

Rob Milne, who previously held engineering and R&D executive positions with Nokia, Vienna Systems, Motorola and Mitel, has been appointed VP of product development.

Gail McBride, the firm's new VP of marketing comes to GenoLogics from ALI Technologies, while David Slater-Kinghorn, who has been named VP of finance, formerly held positions at LifeScan Canada, a Johnson & Johnson Company, CanWel Distribution and Sappi Export Services.

Brandie Yarish has been named manager of human resources, and, to round out the new appointments, James DeGreef, a co-founder of GenoLogics, will assume the position of VP of product management.


Peter Schultz has joined the board of directors at Nanosphere, the life sciences company said this week.

Schultz is currently on the faculty at The Scripps Research Institute in La Jolla, Calif., where he holds the Scripps Family Chair as a professor of chemistry, and is director of the Genomics Institute of the Novartis Research Foundation, also in La Jolla.

Schultz also helped found the Affymax Research Institute, Symyx Technologies, Ambrx, Syrrx, Kalypsys, Phenomix, and Ilypsa.

He holds a BA and a PhD from the California Institute of Technology.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.